Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization, is adding a GMP bioconjugation suite at its commercial biologics facility in Bengaluru.
This new capability will enable Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
- Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies services
- Syngene will be among a handful of CDMOs with full-service capabilities
Syngene International is expanding its capabilities to offer end-to-end ADC development services.
Author's summary: Syngene International adds bioconjugation suite.
More News
- Citation Building for Local SEO | NorthPennNow
- Annual Old Town Gazebo 'Day of the Dead' Event Cancelled
- Residency reform, a priority for the Ministry of Health
- Comment | A spate of dealer anniversaries offers hope amid art market doomerism
- Waymo co-CEO on robotaxi vandalism: 'We're not standing for it' | TechCrunch
- Lululemon Joins NFL Roster, Chasing a Comeback Season
- The Passport relaunches its cocktail and wine bar in the Loop in November
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- LSU has now fired offensive coordinator Joe Sloan - Reveille
- Praia Health’s Kurt Hammond on Powering Providence’s Work With Labcorp